T1D, often written as “TD1” in searches, stands for type 1 diabetes, an autoimmune condition where the body’s immune system destroys the cells in the pancreas that produce insulin. Without insulin, the body cannot move sugar from the bloodstream into cells for energy. An estimated 9.5 million people worldwide live with T1D, and roughly 513,000 new cases are diagnosed each year.
Unlike type 2 diabetes, which develops when the body becomes resistant to insulin over time, type 1 diabetes results from an absolute lack of insulin production. It can appear at any age, though it is most commonly diagnosed in children and young adults. About 1.85 million people with T1D are under 20 years old.
What Happens Inside the Body
Type 1 diabetes is driven by a misdirected immune response. Two types of immune cells, called CD4 and CD8 T cells, attack and destroy the insulin-producing beta cells in the pancreas. These are the same immune cells that normally fight infections, but in T1D they mistakenly treat the body’s own tissue as a threat. By the time symptoms appear, a large portion of beta cells have already been destroyed, and the pancreas can no longer produce enough insulin to regulate blood sugar.
This process unfolds over months or years before someone feels sick. Researchers can now detect it early by testing the blood for autoantibodies, proteins that signal the immune system has begun targeting the pancreas. The presence of these autoantibodies can indicate T1D is developing even before blood sugar levels rise.
Genetics and Risk Factors
Certain genes significantly raise the likelihood of developing T1D. The strongest genetic link involves a set of immune system genes called HLA. People who carry specific variations known as HLA-DR3 and HLA-DR4 face substantially higher odds. Carrying DR4 alone raises risk roughly sevenfold, while having both DR3 and DR4 together pushes the odds ratio above 10, meaning it is more than ten times as likely compared to someone without those markers. This combined genotype is also the most common in children diagnosed at the youngest ages.
Other gene variants are protective. One combination involving HLA-DR2 drops the odds to roughly one-tenth of the baseline risk. Still, genetics alone don’t determine who develops T1D. Environmental triggers, possibly viral infections or other immune stressors, appear to set the autoimmune process in motion in genetically susceptible people. Most individuals diagnosed with T1D have no family history of the disease.
Symptoms and How It’s Diagnosed
The classic symptoms of type 1 diabetes come on relatively quickly: excessive thirst, frequent urination, unexplained weight loss, constant hunger, fatigue, and blurred vision. In children, onset tends to be more abrupt and is more likely to include a dangerous complication called diabetic ketoacidosis (more on that below). Adults diagnosed with T1D sometimes have a slower progression, and are more likely to be initially misdiagnosed with type 2 diabetes. Studies show that adults with new-onset T1D are more likely to be overweight at diagnosis and to have been started on oral diabetes medications before doctors realize the underlying cause is autoimmune.
Diagnosis is confirmed through blood tests. A fasting blood sugar of 126 mg/dL or higher, a random blood sugar of 200 mg/dL or higher with symptoms, or an A1C of 6.5% or above all meet the threshold for diabetes. To distinguish type 1 from type 2, doctors test for diabetes-related autoantibodies. If these autoantibodies are present, the diagnosis is type 1.
Diabetic Ketoacidosis: The Acute Danger
When the body has little or no insulin, it cannot use sugar for fuel and starts breaking down fat at an accelerated rate. This produces acids called ketones, which build up in the blood and can become life-threatening. This condition, diabetic ketoacidosis (DKA), is sometimes the first sign that someone has T1D, especially in children.
DKA is classified by severity. Mild cases involve blood acidity (pH) just below normal, while severe cases push pH below 7.0 with very high ketone levels. Symptoms include nausea, vomiting, abdominal pain, fruity-smelling breath, rapid breathing, and confusion. DKA requires emergency treatment and is the leading cause of death in children with type 1 diabetes. Recognizing the early warning signs of T1D, particularly in kids who are drinking and urinating far more than usual, can prevent this emergency.
Living With T1D: Insulin and Daily Management
Everyone with type 1 diabetes needs insulin to survive. There is no pill or lifestyle change that can replace it. Most people use a combination of two types: a long-acting insulin that provides a steady background level throughout the day, and a rapid-acting insulin taken before meals to handle the sugar from food.
Long-acting insulins begin working within a couple of hours and last 20 to 24 hours or longer, with no sharp peak. This mimics the low, constant insulin output a healthy pancreas provides between meals and overnight. Rapid-acting insulins kick in within 15 minutes and are mostly done working within 3 to 5 hours, covering the blood sugar spike that follows eating. Getting the balance right between these two types is the central daily challenge of managing T1D.
Insulin can be delivered through multiple daily injections using pens or syringes, or through an insulin pump, a small device worn on the body that delivers insulin continuously through a tiny tube under the skin. Pumps can be programmed to adjust the background rate automatically, and newer “closed-loop” systems pair a pump with a continuous glucose monitor to automate much of the dosing.
Continuous Glucose Monitors
Continuous glucose monitors (CGMs) have transformed T1D management over the past decade. These small sensors, worn on the arm or abdomen, measure blood sugar levels every few minutes and send readings to a phone or receiver. The latest models achieve an overall accuracy rate with a margin of error around 8%, meaning the sensor reading is typically very close to an actual blood test. Current sensors last about two weeks before needing replacement.
CGMs show not just a single number but a trend: whether blood sugar is rising, falling, or stable. This real-time information helps people make better decisions about food, exercise, and insulin doses. Alarms can warn of dangerously low or high readings, even during sleep. For many people with T1D, CGMs have reduced both the frequency of dangerous low blood sugar episodes and the anxiety that comes with not knowing what their levels are doing.
Long-Term Complications
Persistently high blood sugar damages blood vessels over time, leading to complications that affect the eyes, kidneys, nerves, and cardiovascular system. In a large study following over 1,500 people with T1D for a median of nearly 12 years, about 39% developed at least one of these complications: diabetic eye disease, kidney disease, or nerve damage. That is a substantial proportion, but the same research found that keeping A1C below 6.5% and blood pressure under 140/90 meaningfully reduced these risks.
Cardiovascular problems, including heart disease, stroke, and poor circulation in the legs, also carry additional consequences. People with T1D who develop one of these large-vessel complications face a significantly higher chance of then developing small-vessel complications like eye or kidney disease. Peripheral artery disease, for instance, tripled the risk of subsequent eye, kidney, or nerve damage in the T1D group studied.
The takeaway from this research is that aggressive management of blood sugar and blood pressure together provides the strongest protection. Tight control in the early years after diagnosis appears especially important for reducing lifetime complication risk.
Treatments That Can Delay Onset
For the first time, a medication exists that can delay the progression from early-stage autoimmunity to full-blown type 1 diabetes. Teplizumab, an immune-modulating treatment approved in 2022, targets the T cells responsible for destroying beta cells. In clinical trials, people at high risk (those already showing autoantibodies and early blood sugar abnormalities) who received teplizumab took a median of 48 months to develop clinical diabetes, compared to 24 months for those who received a placebo. In longer follow-up, the delay extended to nearly 60 months. The effect was strongest in the first year after treatment.
This treatment is specifically for people identified as being in the early stages of T1D before they need insulin. It does not cure or reverse established disease, but it represents a significant shift: for the first time, doctors can intervene during the autoimmune process rather than only managing the consequences after beta cells are already gone. Screening family members of people with T1D for autoantibodies is one way to identify candidates who might benefit.